BiotechTube

REC-2282 + Placebo

Phase 2/3Terminated
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 2

Conditions

Neurofibromatosis Type 2

Trial Timeline

Jun 20, 2022 → Aug 18, 2025

NCT ID
NCT05130866

About REC-2282 + Placebo

REC-2282 + Placebo is a phase 2/3 stage product being developed by Recursion Pharmaceuticals for Neurofibromatosis Type 2. The current trial status is terminated. This product is registered under clinical trial identifier NCT05130866. Target conditions include Neurofibromatosis Type 2.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT05130866Phase 2/3Terminated

Competing Products

20 competing products in Neurofibromatosis Type 2

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
52
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
AZD2014AstraZenecaPhase 2
52
Selumetinib + PlaceboAstraZenecaPhase 2
52
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 3
77
Everolimus (RAD001) , Afinitor®NovartisPhase 2
52
RAD001: EverolimusNovartisPhase 2
52
RAD001, everolimusNovartisPhase 2
52
TasignaNovartisPhase 1
33
TrametinibNovartisPhase 2
52
Everolimus (RAD001)NovartisPhase 2
52
Sutent®/SunitinibPfizerPhase 2
51
Sorafenib (Nexavar)BayerPhase 2
49
PTC299United TherapeuticsPhase 2
49
BinimetinibPacific BiosciencesPhase 2
44

Other Products from Recursion Pharmaceuticals

REC-4881Phase 2
47
REC-3964Phase 2
47
REC-994 + PlaceboPhase 2
47
REC-1245Phase 1/2
36
REC-4881 + PlaceboPhase 1/2
36